Hinova Pharmaceuticals Inc.

Kexin Xu

Ke Chen

Shaohua Zhang

Yuanwei Chen

Xinghai Li

Lei Fan

Tongchuan Luo

Xiaoquan Wu

Fei Wang

Wu Du

Yongxu Huo

Zhilin Tu

Chengzhi Zhang

The compound of formula (I) has a good inhibitory effect on the proliferation of human prostate cancer cells CWR22RV1 and breast cancer cells; and combined use of the compound with an androgen receptor inhibitor HC-1119 significantly enhances the inhibitory effect on prostate cancer cells, and the inhibitory effect increases with increased concentration. The compound of formula (I) can not only be used independently to prepare an antineoplastic agent but can also be used in combination with other agents having antineoplastic effects, such as an androgen receptor inhibitor, or other targeting drugs etc., to prepare an antineoplastic agent having stronger therapeutic effects, especially an agent for treating prostate cancer and breast cancer.

BRD4 inhibitor as well as a preparative method and use thereof

Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumors, autoimmune or inflammatory diseases and viral infection, and in particular an anti-prostate cancer drug. 

BRD4 inhibitor

Quinoline compounds and salts, hydrates or solvates serving as a selective uric acid reabsorption inhibitor, can be used in the treatment of hyperuricemia and gout by promoting uric acid to excrete from the body and reducing serum uric acid. Such compounds have the effect of reducing the uric acid in the animal body and human body.

Quinoline compounds, preparation methods thereof, and uses thereof as urate transporter inhibitor drug

Growing community of inventors

Sichuan, China

Kexin Xu